What medications can cause hair loss is a question many patients ask when they notice unexpected shedding or thinning. Drug-induced alopecia is more common than often recognised, affecting people taking a wide range of prescription and over-the-counter medicines — from anticoagulants and antidepressants to chemotherapy agents and hormonal therapies. Understanding which drugs are implicated, how they affect the hair growth cycle, and what steps to take can help patients and clinicians respond promptly and appropriately. This article outlines the key drug classes involved, how to distinguish medication-related hair loss from other causes, and the management options available within UK clinical practice.
Summary: Many medications can cause hair loss, including chemotherapy agents, anticoagulants, retinoids, beta-blockers, sodium valproate, antidepressants, and certain hormonal therapies, typically by disrupting the normal hair growth cycle.
- Drug-induced alopecia most commonly presents as telogen effluvium — diffuse shedding beginning six to twelve weeks after starting the offending medication.
- Chemotherapy agents cause anagen effluvium by directly disrupting the active growth phase, often producing rapid and pronounced hair loss across the scalp and body.
- Sodium valproate, beta-blockers, anticoagulants, retinoids, and certain antidepressants all carry a recognised association with hair loss as documented in their Summaries of Product Characteristics.
- Drug-induced hair loss is usually reversible once the causative medicine is stopped or the dose reduced, with regrowth typically beginning within three to six months.
- Patients should not stop medication abruptly without medical advice; a GP or prescribing clinician should assess the cause and consider blood tests to exclude other contributing factors.
- Suspected drug-related hair loss can be reported to the MHRA via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Which Medications Are Commonly Linked to Hair Loss
Chemotherapy agents, anticoagulants, retinoids, beta-blockers, sodium valproate, antidepressants, antithyroid drugs, and certain hormonal therapies are among the most commonly implicated drug classes in drug-induced alopecia.
A wide range of prescription and over-the-counter medicines have been associated with hair loss, a condition known medically as drug-induced alopecia. Understanding which medications carry this risk can help patients and clinicians identify the likely cause and respond appropriately.
Not sure if this is normal? Chat with one of our pharmacists →
Some of the most frequently implicated drug classes include:
-
Chemotherapy agents (e.g., cyclophosphamide, doxorubicin): These are among the most well-known causes, often producing pronounced, diffuse hair loss by directly disrupting the active growth phase of the hair cycle.
-
Anticoagulants (e.g., warfarin, heparin): Telogen effluvium can occur within weeks to a few months of starting treatment. Direct-acting oral anticoagulants (DOACs) such as apixaban and rivaroxaban have been reported in post-marketing data, though causality remains uncertain.
-
Retinoids (e.g., isotretinoin, acitretin): Used for skin conditions, these can trigger hair thinning, particularly at higher doses, as documented in their Summary of Product Characteristics (SmPC).
-
Beta-blockers (e.g., propranolol, atenolol): Commonly prescribed for cardiovascular conditions, these have a recognised association with hair loss, though the precise mechanism is not fully established.
-
Antithyroid drugs (e.g., carbimazole): May cause shedding, though thyroid disease itself can also affect hair and should be considered as a contributing factor.
-
Antidepressants and mood stabilisers (e.g., lithium, fluoxetine, sertraline): Hair loss is listed as a possible side effect in relevant SmPCs, though it is not universal.
-
Hormonal therapies: Some combined oral contraceptives containing androgenic progestogens may exacerbate hair thinning in susceptible individuals. Note that spironolactone, an antiandrogen, is commonly used in UK practice to treat female pattern hair loss; hair shedding as an adverse effect is uncommon and usually transient.
-
Anticonvulsants (e.g., sodium valproate): Valproate in particular is well documented as a cause of hair thinning, as noted in its SmPC.
-
Other recognised drug classes: Methotrexate, interferons, tyrosine kinase inhibitors and other immunotherapies, amiodarone, certain antiretrovirals (e.g., zidovudine), and some antihypertensives have also been associated with hair loss, though the strength of evidence varies.
It is important to note that not everyone taking these medicines will experience hair loss. Individual susceptibility varies considerably based on genetics, dose, duration of treatment, and overall health. If you suspect a medication is affecting your hair, speak with your GP or prescribing clinician before making any changes to your treatment. Suspected side effects can be reported to the MHRA via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or through the Yellow Card app.
| Drug Class | Example Medicines | Type of Hair Loss | Typical Onset | Reversibility |
|---|---|---|---|---|
| Chemotherapy agents | Cyclophosphamide, doxorubicin | Anagen effluvium — rapid, diffuse; may affect brows, lashes, body hair | Days to weeks after treatment | Usually reverses after treatment ends; scalp cooling may reduce severity |
| Anticoagulants | Warfarin, heparin, apixaban, rivaroxaban | Telogen effluvium — diffuse shedding | Weeks to a few months after starting | Often improves; do not stop anticoagulants without medical advice |
| Retinoids | Isotretinoin, acitretin | Telogen effluvium — diffuse thinning, dose-dependent | Weeks to months | Generally reverses on dose reduction or cessation |
| Anticonvulsants | Sodium valproate | Telogen effluvium — diffuse thinning; well documented in SmPC | Weeks to months after starting | May improve with dose adjustment; consult prescribing clinician |
| Beta-blockers | Propranolol, atenolol | Telogen effluvium — mechanism not fully established | Weeks to months | Often reversible; do not stop without medical advice |
| Antidepressants & mood stabilisers | Lithium, fluoxetine, sertraline | Telogen effluvium — listed in SmPCs; not universal | Weeks to months | Variable; discuss alternatives with GP before stopping |
| Hormonal therapies | Combined oral contraceptives (androgenic progestogens) | May exacerbate androgenetic alopecia in susceptible individuals | Variable | May improve on switching to a less androgenic preparation; consult GP |
How Drug-Induced Hair Loss Differs From Other Types
Drug-induced hair loss typically causes diffuse shedding (telogen effluvium) beginning six to twelve weeks after starting a medication, distinguishing it from the patterned loss of androgenetic alopecia or the patchy bald patches of alopecia areata.
Hair loss has many potential causes, including androgenetic alopecia (male or female pattern baldness), alopecia areata (an autoimmune condition), nutritional deficiencies, thyroid disorders, and significant physical or emotional stress. Drug-induced hair loss has several distinguishing features that can help differentiate it from these other causes.
The most common pattern seen with medication-related hair loss is telogen effluvium, where a large number of hair follicles are prematurely pushed into the resting (telogen) phase of the hair growth cycle. This typically results in diffuse shedding across the scalp rather than patchy or patterned loss. A positive hair-pull test (more than six hairs removed with gentle traction) and the absence of scalp scarring are characteristic findings. Shedding usually begins six to twelve weeks after starting the offending medication, which can make the connection less obvious to patients.
A less common but more severe form is anagen effluvium, which occurs when a drug directly disrupts the active growth (anagen) phase of the hair cycle. This is the mechanism behind chemotherapy-related hair loss and tends to be more rapid and pronounced, sometimes affecting eyebrows, eyelashes, and body hair as well.
Key distinguishing features of drug-induced hair loss include:
-
Temporal relationship to starting or increasing a medication
-
Diffuse pattern rather than localised patches or a receding hairline
-
Reversibility in most cases once the drug is stopped or the dose reduced
-
Absence of scalp inflammation, scarring, or other dermatological signs
In contrast, androgenetic alopecia follows a predictable patterned distribution, and alopecia areata typically presents with well-defined, smooth bald patches.
Red flags requiring prompt clinical assessment or dermatology referral include:
-
Scalp inflammation, pustules, pain, or tenderness
-
Signs of scarring (loss of follicular openings on the scalp)
-
Rapid or extensive hair loss
-
Involvement of eyebrows or eyelashes without a clear drug cause
-
Hair loss in a child
-
Diagnostic uncertainty after initial assessment
A thorough medication history is a critical part of any clinical assessment for hair loss. NICE Clinical Knowledge Summaries (CKS), the Primary Care Dermatology Society (PCDS), and the British Association of Dermatologists (BAD) all provide guidance on the systematic assessment of alopecia in primary care.
Why Certain Medicines Affect Hair Growth
Medications disrupt hair growth by interfering with the hair cycle — cytotoxic agents halt the anagen (growth) phase directly, while others prematurely push follicles into the telogen (resting) phase, though precise mechanisms vary and are not always fully established.
To understand why some medications cause hair loss, it helps to appreciate the biology of the hair follicle. Hair grows in a cyclical pattern comprising three main phases: anagen (active growth, lasting two to six years), catagen (a brief transitional phase), and telogen (resting phase, lasting approximately three months), after which the hair sheds naturally and the cycle restarts.
Different drugs interfere with this cycle through distinct mechanisms:
-
Cytotoxic agents used in chemotherapy target rapidly dividing cells throughout the body, including those in the hair matrix. This directly disrupts the anagen phase, causing swift and often extensive hair loss — a process known as anagen effluvium.
-
Hormonal medications: Contraceptives containing androgenic progestogens may exacerbate androgenetic alopecia in susceptible individuals by altering the androgen-to-oestrogen balance, which plays a role in regulating follicle sensitivity. Not all hormonal therapies carry this risk equally.
-
Anticoagulants and retinoids are thought to interfere with normal progression through the hair cycle, pushing follicles prematurely into telogen, though the precise mechanisms are not fully established and are based largely on clinical observation and SmPC data.
-
Sodium valproate: The mechanism by which valproate causes hair thinning is not fully understood. Some hypotheses involve effects on follicle metabolism, but these remain unconfirmed; the association is well documented in the SmPC and clinical literature.
-
Beta-blockers: The mechanism is uncertain. Various hypotheses have been proposed, but none is conclusively established; the association is recognised in SmPCs and pharmacovigilance data.
In many cases the exact mechanism is not fully understood, and not every reported association has confirmed causality. The MHRA Yellow Card Scheme collects reports of suspected adverse drug reactions, including hair loss, contributing to ongoing pharmacovigilance. Patients and healthcare professionals are encouraged to report suspected side effects at www.mhra.gov.uk/yellowcard or via the Yellow Card app.
Experiencing these side effects? Our pharmacists can help you navigate them →
What to Do If You Notice Hair Loss While on Medication
Contact your GP or prescribing clinician rather than stopping your medication abruptly; they will take a medication history and may arrange blood tests to exclude thyroid dysfunction, anaemia, or iron deficiency as contributing causes.
Noticing increased hair shedding or thinning whilst taking a medication can be distressing, but it is important to approach the situation calmly and methodically. The first and most important step is not to stop your medication abruptly without medical advice, as doing so could have serious consequences depending on the condition being treated.
Contact your GP or prescribing clinician if you notice:
-
A significant or sudden increase in hair shedding
-
Visible thinning or bald patches developing
-
Hair loss beginning within weeks to months of starting a new medicine
-
Hair loss accompanied by other new symptoms such as fatigue, weight changes, or skin changes
-
Any of the red flags listed above (scalp inflammation, scarring, pain, rapid progression, or hair loss in a child)
Your clinician will typically take a detailed medication history, including the timing of when each drug was started or its dose changed. They may also arrange blood tests to rule out other contributing causes, such as:
-
Thyroid function tests (TSH, free T4)
-
Full blood count to check for anaemia
-
Ferritin levels, as iron deficiency is a common and treatable cause of hair loss
-
Vitamin D, zinc, and B12 levels where nutritional deficiency is clinically suspected
Additional micronutrient tests are targeted rather than routine and should be guided by clinical assessment.
In some cases, referral to a dermatologist is appropriate — particularly if the diagnosis is unclear, hair loss is severe or rapidly progressive, scarring is suspected, or the patient is a child. NICE CKS guidance on diffuse hair loss and telogen effluvium, alongside PCDS and BAD resources, provides a systematic framework for assessment that considers all potential causes before attributing symptoms to a single factor. Keeping a simple diary noting when hair loss began, how much is shedding, and any recent medication changes can be a helpful tool to share with your clinician.
Managing Hair Loss and Reviewing Your Treatment Options
Management depends on severity and the importance of the medication; options include dose reduction, switching to an alternative drug, scalp cooling for chemotherapy patients, topical minoxidil (off-label), and cosmetic or psychological support.
The management of drug-induced hair loss depends on several factors, including the severity of the hair loss, the importance of the medication to the patient's health, and whether alternative treatments are available. In many cases, hair loss is reversible once the causative drug is discontinued or the dose is reduced, with regrowth typically beginning within three to six months.
However, stopping or switching a medication is not always straightforward or appropriate. For example, patients on anticoagulants for atrial fibrillation or those undergoing chemotherapy for cancer cannot simply discontinue treatment. In these situations, the focus shifts to supportive management and patient reassurance:
-
Scalp care: Using gentle, sulphate-free shampoos and avoiding excessive heat styling or tight hairstyles can minimise additional mechanical stress on fragile hair.
-
Nutritional support: Ensuring adequate intake of iron, zinc, biotin, and protein supports overall hair health. Supplements should only be taken if a deficiency has been confirmed by blood tests, in line with NHS and NICE CKS advice.
-
Scalp cooling (cold caps): For patients receiving chemotherapy, scalp cooling is available in many NHS settings and can reduce the severity of chemotherapy-induced hair loss. Macmillan Cancer Support and NHS resources provide further information on eligibility and availability.
-
Cosmetic solutions: Wigs, hairpieces, and scalp micropigmentation can provide significant psychological benefit during periods of hair loss. NHS support for wigs and fabric supports is available in certain circumstances; in England, standard charges apply unless the patient is exempt (for example, those receiving certain benefits or undergoing NHS cancer treatment). Eligibility criteria and charges vary by Integrated Care Board (ICB). The NHS Business Services Authority (NHSBSA) provides up-to-date information on help with health costs, including wigs and fabric supports.
-
Topical minoxidil: Available from pharmacies without a prescription in the UK (2% or 5% solution or foam), minoxidil may help stimulate regrowth in some cases. It is not specifically licensed for drug-induced telogen effluvium, and its use for this indication is off-label with limited supporting evidence. Discuss with your GP or pharmacist before starting.
If an alternative medication exists that carries a lower risk of hair loss, your clinician may consider switching, provided it is clinically appropriate. Any such decision should be made collaboratively, weighing the benefits of the current treatment against the impact of hair loss on quality of life. Psychological support, including referral to a counsellor or organisations such as Alopecia UK, can also be valuable for those significantly affected.
Frequently Asked Questions
How long does it take for medication-related hair loss to start?
Drug-induced hair loss caused by telogen effluvium typically begins six to twelve weeks after starting or increasing the dose of the offending medication. This delay often makes the connection less obvious, so it is worth reviewing any medicines started in the preceding three months if you notice unexplained shedding.
Will my hair grow back after stopping the medication that caused hair loss?
In most cases, drug-induced hair loss is reversible once the causative medication is discontinued or the dose reduced, with regrowth typically beginning within three to six months. Recovery depends on the drug involved, how long it was taken, and individual factors such as overall health and any underlying hair conditions.
Can antidepressants cause hair loss, and is it permanent?
Yes, some antidepressants — including fluoxetine, sertraline, and lithium — list hair loss as a possible side effect in their Summaries of Product Characteristics, though it does not affect everyone. The hair loss is generally not permanent and tends to resolve once the medication is stopped or switched, but you should always discuss any changes with your prescribing clinician first.
What is the difference between telogen effluvium and anagen effluvium caused by drugs?
Telogen effluvium is diffuse shedding caused by follicles being prematurely pushed into the resting phase, typically seen with anticoagulants, beta-blockers, and valproate, starting weeks after exposure. Anagen effluvium is more rapid and severe, caused by chemotherapy agents directly disrupting the active growth phase, and can affect eyebrows, eyelashes, and body hair as well as the scalp.
Can I use minoxidil to treat hair loss caused by my medication?
Topical minoxidil is available without a prescription from UK pharmacies and may help stimulate regrowth in some cases, but its use for drug-induced telogen effluvium is off-label with limited supporting evidence. Speak with your GP or pharmacist before starting minoxidil to ensure it is appropriate for your situation and to address any underlying cause first.
Should I report hair loss as a side effect of my medication?
Yes — suspected side effects, including hair loss, can be reported to the MHRA via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or through the Yellow Card app. Both patients and healthcare professionals are encouraged to report, as this data contributes to ongoing drug safety monitoring in the UK.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
